Pricing

Cyclerion Therapeutics Inc (CYCN)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Peter M. Hecht
Employees:
30
301 BINNEY STREET, CAMBRIDGE, MA, 02142
617-621-7722
Stock Split History
DateRatio
2023-05-16 1:20
Cyclerion Therapeutics, Inc. engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available